Home › Funds › MUTUAL FUND SERIES TRUST › AlphaCentric Life Sciences and Healthcare Fund
Fund family: MUTUAL FUND SERIES TRUST · Filed by MUTUAL FUND SERIES TRUST (CIK 1355064) · SEC series S000067055
Share classes and tickers: LYFAX (C000215731), LYFCX (C000215729), LYFIX (C000215730)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 477 with, 7 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 2 FOR, 5 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as MUTUAL FUND SERIES TRUST’s manager page (12,253 ballot items across 22 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | MUTUAL FUND SERIES TRUST | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 82.6% | 437 | 93.0% | 10,912 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 17.7% | 334 |
Each ballot item this fund voted is set against the votes of the other MUTUAL FUND SERIES TRUST funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most MUTUAL FUND SERIES TRUST funds on 2 items (10.5% of the 19 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most MUTUAL FUND SERIES TRUST funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Incyte Corporation | 2026-06-08 | Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. Baker | For | AGAINST — 3 of 3 MUTUAL FUND SERIES TRUST funds | For | Elected, 80.9% support |
| Gilead Sciences, Inc. | 2026-04-30 | Shareholder To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. | Against | FOR — 2 of 3 MUTUAL FUND SERIES TRUST funds | For | Not approved, 27.1% support |
Download all 2 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 65.7% of this fund’s 484 such votes could be given a sector; the other 166 (34.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 318 | 7 | 2.2% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 241 | 0 |
| Audit-related | 58 | 0 |
| Say-on-Pay | 47 | 0 |
| Capital Structure | 45 | 0 |
| Compensation | 39 | 0 |
| Corporate Governance | 24 | 6 |
| Other | 20 | 0 |
| Extraordinary Transactions | 8 | 0 |
| Shareholder Rights and Defenses | 3 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Gilead Sciences, Inc. | April 30, 2026 | $3M | 15 | 3 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $3M | 15 | 1 |
| Incyte Corporation | June 8, 2026 | $2M | 10 | 0 |
| Neurocrine Biosciences, Inc. | May 27, 2026 | $2M | 6 | 0 |
| Oruka Therapeutics, Inc. | June 2, 2026 | $1M | 4 | 0 |
| Protagonist Therapeutics, Inc. | June 17, 2026 | $1M | 5 | 0 |
| Amgen Inc. | May 19, 2026 | $1M | 15 | 1 |
| Insmed Incorporated | May 13, 2026 | $1M | 4 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| April 23, 2026 | IQVIA Holdings Inc. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | Against | For |
487 ballot items at 64 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, AlphaCentric Life Sciences and Healthcare Fund (LYFAX) voted at 64 shareholder meetings of 61 companies, on 487 ballot items in all. Where management made a recommendation, the fund followed it on 98.6% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (6 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals less often than MUTUAL FUND SERIES TRUST's funds as a whole (82.6% against 93.0%). It voted differently from most MUTUAL FUND SERIES TRUST funds on 2 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of MUTUAL FUND SERIES TRUST’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.